Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10844529 | 0.84 | CASP1 (0.50) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL10845878 | 0.82 | CYP2A6 (0.47) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL10844756 | 0.76 | CYP1A2 (0.42) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL581664 | 0.75 | CASP1 (0.56) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL1752831 | 0.75 | SMARCA2 (0.59) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL1752913 | 0.75 | MEN1 (0.54) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL30271446 | 0.75 | MEN1 (0.82) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL30271447 | 0.75 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL30271455 | 0.75 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAADRB2MEN1KMT2A | |
| SCHEMBL5827038 | 0.74 | ALDH1A1 (0.54) | SMN1; SMN2LMNAADRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101805298-A | Novel aryl-with heteroaryl-piperazine | HIGH POINT PHARMACEUTICALS LLC | 2010-08-18 | — | — | CN | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | disclosed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| CN-1628109-A | Novel aryl-and heteroaryl-piperazines | NOVO NORDISK AS (DK) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| US-4631280-A | Pyridazine derivatives having a psychotropic action, and medicaments in which they are present | SANOFI (FR) | 1986-12-23 | — | — | US | disclosed |
| US-4565814-A | Pyridazine derivatives having a psychotropic action and compositions | SANOFI (FR) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | SMN1; SMN2 4208/4885LMNA 4775/4885ADRB2 36/4885 |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | SMN1; SMN2 4363/4885LMNA 1243/4885ADRB2 62/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | SMN1; SMN2 3315/4885LMNA 3146/4885ADRB2 60/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | SMN1; SMN2 4208/4885LMNA 4775/4885ADRB2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.